Travere Therapeutics (TVTX) AI Stock Analysis

• Market Cap: $2.69B
• Dividend Yield: N/A
• Average Volume (3M): 2.58M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.42
• Revenue Growth: 114.22%
• EPS Growth: 77.02%
• Country: US
• Employees: 385
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.28
• Shares Outstanding: 89,472,330
• 10 Day Avg. Volume: 1,848,672
• 30 Day Avg. Volume: 2,579,888
• PEG Ratio: -0.02
• Price to Book (P/B): 23.26
• Price to Sales (P/S): 5.89
• P/FCF Ratio: -4.06
• Enterprise Value/Market Cap: 1.15
• Enterprise Value/Revenue: 7.08
• Enterprise Value/Gross Profit: 7.25
• Enterprise Value/Ebitda: -136.58
• 1Y Price Target: $41.92
• Price Target Upside: 38.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): 0.76
• Revenue Forecast (FY): $684.63M

• Rating: 56 Neutral
• Price Target: $35.00 ▲(15.59% Upside)

Travere Therapeutics' overall stock score reflects strong earnings call performance and positive technical indicators, offset by weak financial performance and valuation concerns. The potential FDA approval for FILSPARI is a significant positive factor, but high leverage and lack of profitability remain critical risks.

Positive Factors

Revenue Growth

Strong revenue growth from FILSPARI indicates robust demand and market penetration, supporting long-term revenue expansion and business sustainability.

Regulatory Advancements

Regulatory advancements enhance product accessibility and safety perception, potentially accelerating market adoption and competitive positioning.

Clinical Trial Success

Successful clinical trials bolster the drug's efficacy profile, improving its market potential and addressing significant unmet medical needs in kidney disorders.

Negative Factors

High Leverage

High leverage can strain financial flexibility and increase risk, potentially impacting the company's ability to invest in growth and innovation.

Profitability Challenges

Ongoing profitability challenges may hinder long-term financial health and limit resources available for strategic initiatives and R&D investments.

Negative Cash Flow

Negative cash flow can constrain operational capabilities and necessitate external financing, potentially affecting strategic flexibility and growth prospects.

Travere Therapeutics Business Overview & Revenue Model

Company Description

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

How the Company Makes Money

Travere Therapeutics generates revenue primarily through the sale of its pharmaceutical products, particularly those that have received regulatory approval and are commercially available. The company may also earn income through partnerships with other pharmaceutical companies for co-development and commercialization of drug candidates, which can include milestone payments and royalties. Additionally, government grants and funding from research initiatives may contribute to its revenue streams. The success of Travere's revenue model heavily relies on the efficacy and market acceptance of its therapeutic products, as well as the company's ability to navigate the regulatory landscape effectively.

Travere Therapeutics Financial Statement Overview

Summary

Strong top-line momentum (30.54% TTM revenue growth; 54.01% TTM gross margin) is offset by weak financial durability: high leverage (4.48 debt-to-equity) and negative operating/free cash flow with worsening free cash flow growth (-44.68% TTM).

Income Statement

Travere Therapeutics shows a strong revenue growth rate of 30.54% TTM, indicating positive sales momentum. However, the company struggles with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin is relatively healthy at 54.01% TTM, but the persistent negative net income highlights ongoing challenges in achieving operational efficiency.

Balance Sheet

The company has a high debt-to-equity ratio of 4.48 TTM, indicating significant leverage and potential financial risk. The return on equity is negative, reflecting losses that erode shareholder value. Although the equity ratio is not provided, the high leverage suggests limited financial flexibility.

Cash Flow

Travere Therapeutics faces challenges with negative operating and free cash flows, impacting liquidity. The free cash flow to net income ratio is positive, suggesting some ability to cover net losses, but the negative free cash flow growth rate of -44.68% TTM indicates worsening cash flow conditions.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	435.83M	233.18M	145.24M	109.46M	131.84M	198.32M
Gross Profit	425.49M	225.43M	133.79M	105.04M	128.02M	192.19M
EBITDA	-22.58M	-265.77M	-326.25M	-299.42M	-184.46M	-145.16M
Net Income	-88.54M	-321.55M	-111.40M	-278.48M	-180.09M	-169.43M
Balance Sheet
Total Assets	538.58M	594.13M	788.91M	672.59M	776.63M	607.44M
Cash, Cash Equivalents and Short-Term Investments	254.53M	370.70M	566.85M	450.25M	552.88M	361.59M
Total Debt	329.75M	401.58M	404.78M	407.49M	261.99M	244.03M
Total Liabilities	465.02M	535.05M	588.10M	629.73M	474.52M	396.23M
Stockholders Equity	73.56M	59.08M	200.81M	42.85M	302.11M	211.21M
Cash Flow
Free Cash Flow	-80.33M	-338.69M	-321.61M	-214.66M	-38.94M	-162.59M
Operating Cash Flow	-58.61M	-237.47M	-280.02M	-186.29M	-14.79M	-42.74M
Investing Cash Flow	52.42M	99.33M	55.78M	-32.55M	-137.62M	-61.33M
Financing Cash Flow	78.97M	139.42M	218.75M	117.57M	231.68M	127.71M

Travere Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 30.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVTX, the sentiment is Neutral. The current price of 30.28 is below the 20-day moving average (MA) of 32.49, below the 50-day MA of 34.31, and above the 200-day MA of 23.81, indicating a neutral trend. The MACD of -1.63 indicates Positive momentum. The RSI at 41.28 is Neutral, neither overbought nor oversold. The STOCH value of 90.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TVTX.

Travere Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	60 Neutral	$3.23B	-71.79	-28.17%	―	129.21%	80.35%
TARS	60 Neutral	$2.89B	-31.88	-28.35%	―	182.44%	47.21%
TVTX	56 Neutral	$2.69B	-27.92	-410.78%	―	114.22%	77.02%
IRON	52 Neutral	$3.10B	―	-34.78%	―	―	-34.96%
RXRX	52 Neutral	$2.39B	-2.47	-91.06%	―	-32.98%	-18.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GLPG	47 Neutral	$2.29B	-4.58	-16.45%	―	―	―

Travere Therapeutics Corporate Events

FDA Extends Review Timeline for Travere’s FILSPARI sNDA

On January 13, 2026, Travere Therapeutics announced that the U.S. Food and Drug Administration extended the review timeline for the supplemental New Drug Application for FILSPARI in focal segmental glomerulosclerosis, moving the target action date to April 13, 2026 after the company submitted additional data to further characterize the drug’s clinical benefit. The FDA classified these new materials as a Major Amendment but did not request further safety or manufacturing information, and the filing rests on clinical evidence from the large Phase 3 DUPLEX study and Phase 2 DUET study, which showed significant reductions in proteinuria and clinically meaningful benefits versus irbesartan despite DUPLEX not meeting its primary eGFR slope endpoint, underscoring both the potential of FILSPARI to become the first indicated therapy for FSGS and the regulatory scrutiny around demonstrating long‑term kidney function outcomes in this rare disease population.

The most recent analyst rating on (TVTX) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Travere Therapeutics stock, see the TVTX Stock Forecast page.